BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30291653)

  • 1. Evaluation of Focal Laser Ablation of Prostate Cancer Using High Spectral and Spatial Resolution Imaging: A Pilot Study.
    Wang S; Fan X; Yousuf A; Eggener SE; Karczmar G; Oto A
    J Magn Reson Imaging; 2019 May; 49(5):1374-1380. PubMed ID: 30291653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy.
    Sun C; Wang S; Chatterjee A; Medved M; Eggener S; Karczmar GS; Oto A
    Eur Radiol; 2021 Jan; 31(1):325-332. PubMed ID: 32785769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of tumor coverage after MR-guided prostate focal laser ablation therapy.
    Knull E; Oto A; Eggener S; Tessier D; Guneyli S; Chatterjee A; Fenster A
    Med Phys; 2019 Feb; 46(2):800-810. PubMed ID: 30447155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year Outcomes Following Focal Laser Ablation of Localized Prostate Cancer.
    Chao B; Llukani E; Lepor H
    Eur Urol Oncol; 2018 Jun; 1(2):129-133. PubMed ID: 31100236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI-guided focal laser ablation for prostate cancer followed by radical prostatectomy: correlation of treatment effects with imaging.
    Bomers JGR; Cornel EB; Fütterer JJ; Jenniskens SFM; Schaafsma HE; Barentsz JO; Sedelaar JPM; Hulsbergen-van de Kaa CA; Witjes JA
    World J Urol; 2017 May; 35(5):703-711. PubMed ID: 27541586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MR imaging-guided focal laser ablation for prostate cancer: phase I trial.
    Oto A; Sethi I; Karczmar G; McNichols R; Ivancevic MK; Stadler WM; Watson S; Eggener S
    Radiology; 2013 Jun; 267(3):932-40. PubMed ID: 23440319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial.
    Natarajan S; Raman S; Priester AM; Garritano J; Margolis DJ; Lieu P; Macairan ML; Huang J; Grundfest W; Marks LS
    J Urol; 2016 Jul; 196(1):68-75. PubMed ID: 26748164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward mechatronic MRI-guided focal laser ablation of the prostate: Robust registration for improved needle delivery.
    Knull E; Park CKS; Bax J; Tessier D; Fenster A
    Med Phys; 2023 Mar; 50(3):1259-1273. PubMed ID: 36583505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of Multiparametric MRI for Predicting Residual Clinically Significant Prostate Cancer After Focal Laser Ablation.
    Felker ER; Raman SS; Lu DSK; Tuttle M; Margolis DJ; ElKhoury FF; Sayre J; Marks LS
    AJR Am J Roentgenol; 2019 Dec; 213(6):1253-1258. PubMed ID: 31361529
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer.
    Eggener SE; Yousuf A; Watson S; Wang S; Oto A
    J Urol; 2016 Dec; 196(6):1670-1675. PubMed ID: 27449263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance image-guided focal laser ablation in clinically localized prostate cancer: safety and efficacy.
    Al-Hakeem Y; Raz O; Gacs Z; Maclean F; Varol C
    ANZ J Surg; 2019 Dec; 89(12):1610-1614. PubMed ID: 31679182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focal Laser Ablation of Prostate Cancer: Feasibility of Magnetic Resonance Imaging-Ultrasound Fusion for Guidance.
    Natarajan S; Jones TA; Priester AM; Geoghegan R; Lieu P; Delfin M; Felker E; Margolis DJA; Sisk A; Pantuck A; Grundfest W; Marks LS
    J Urol; 2017 Oct; 198(4):839-847. PubMed ID: 28396184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complications, Recovery, and Early Functional Outcomes and Oncologic Control Following In-bore Focal Laser Ablation of Prostate Cancer.
    Lepor H; Llukani E; Sperling D; Fütterer JJ
    Eur Urol; 2015 Dec; 68(6):924-6. PubMed ID: 25979568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy.
    Lindner U; Lawrentschuk N; Weersink RA; Davidson SR; Raz O; Hlasny E; Langer DL; Gertner MR; Van der Kwast T; Haider MA; Trachtenberg J
    Eur Urol; 2010 Jun; 57(6):1111-4. PubMed ID: 20346578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of 3.0T magnetic resonance imaging-guided laser ablation of a cadaveric prostate.
    Woodrum DA; Gorny KR; Mynderse LA; Amrami KK; Felmlee JP; Bjarnason H; Garcia-Medina OI; McNichols RJ; Atwell TD; Callstrom MR
    Urology; 2010 Jun; 75(6):1514.e1-6. PubMed ID: 20381834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver tumor laser ablation - increase in the subacute ablation lesion volume detected with post procedural MRI.
    Sequeiros RB; Kariniemi J; Ojala R; Chengli L; Haapea M; Sequeiros AB; Tervonen O
    Acta Radiol; 2010 Jun; 51(5):505-11. PubMed ID: 20429757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoscopic laser ablation of the prostate: MR appearances during and after treatment and their relation to clinical outcome.
    deSouza NM; Flynn RJ; Coutts GA; Gilderdale DJ; Hall AS; Puni R; Chui M; Harris DN; Kiely EA
    AJR Am J Roentgenol; 1995 Jun; 164(6):1429-34. PubMed ID: 7538727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Focal Ablation of Magnetic Resonance Imaging Defined Prostate Cancer Using Magnetic Resonance Imaging Controlled Transurethral Ultrasound Therapy with Prostatectomy as the Reference Standard.
    Ramsay E; Mougenot C; Staruch R; Boyes A; Kazem M; Bronskill M; Foster H; Sugar L; Haider M; Klotz L; Chopra R
    J Urol; 2017 Jan; 197(1):255-261. PubMed ID: 27545572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
    Chin JL; Billia M; Relle J; Roethke MC; Popeneciu IV; Kuru TH; Hatiboglu G; Mueller-Wolf MB; Motsch J; Romagnoli C; Kassam Z; Harle CC; Hafron J; Nandalur KR; Chronik BA; Burtnyk M; Schlemmer HP; Pahernik S
    Eur Urol; 2016 Sep; 70(3):447-55. PubMed ID: 26777228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
    Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
    AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.